
Why Western pharma is sleeping on China's circular RNA revolution
Episode 209
RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be circular RNA. CircRNA is more stable than linear mRNA, longer-lasting in the body, and potentially re-dosable. And one company has quietly built what may be the most advanced independent circRNA platform in the world — and with barely a single line of English-language press coverage, until now. My guest today is Dr. Lu Gao, CEO of Therorna Inc., a clinical-stage biotech headquartered in Beijing and Shanghai. The company recently presented three posters at ASGCT in Boston, and their lead program has just entered a first-in-human trial. We're going to talk about the science, the clinical strategy, and why Western pharma hasn't paid enough attention to what's being built in China. 01:33 Meet Lu Gao and Therorna 09:29 How Therorna's approach differs 15:42 How TI-0032 reprograms T cells in the body 21:22 Off-the-shelf and re-dosable: what it means for patients 24:38 Why no Chinese biotech has landed a major in vivo deal 31:27 What a successful US IND clearance would mean Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: The therapeutic potential of circular RNA: Could it soon trump mRNA technology?
Publisher
Beyond Biotech - the podcast from Labiotech
Published
August 7, 2026
Duration
36 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Labiotech
Beyond Biotech - the podcast from Labiotech
@beyondbiotechthepodcastfroml
#westernpharma #sleeping #chinascircularrna
